Conservest Capital Advisors Inc. Buys 5,000 Shares of COMPASS Pathways PLC Sponsored ADR $CMPS

Conservest Capital Advisors Inc. boosted its stake in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 32.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 20,363 shares of the company’s stock after acquiring an additional 5,000 shares during the quarter. Conservest Capital Advisors Inc.’s holdings in COMPASS Pathways were worth $57,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Woodline Partners LP grew its holdings in COMPASS Pathways by 279.9% during the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock worth $5,019,000 after acquiring an additional 1,292,927 shares during the last quarter. Polar Asset Management Partners Inc. bought a new stake in COMPASS Pathways during the 1st quarter worth about $657,000. GAMMA Investing LLC boosted its stake in shares of COMPASS Pathways by 93.6% in the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock valued at $30,000 after purchasing an additional 5,003 shares during the last quarter. 22NW LP bought a new position in shares of COMPASS Pathways in the 1st quarter valued at about $1,849,000. Finally, ARK Investment Management LLC boosted its stake in shares of COMPASS Pathways by 4.0% in the 1st quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company’s stock valued at $5,162,000 after purchasing an additional 68,601 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Stock Up 0.6%

COMPASS Pathways stock opened at $6.28 on Friday. The company’s 50 day simple moving average is $5.46 and its 200 day simple moving average is $4.46. COMPASS Pathways PLC Sponsored ADR has a fifty-two week low of $2.25 and a fifty-two week high of $7.09. The firm has a market capitalization of $602.50 million, a price-to-earnings ratio of -3.41 and a beta of 2.21. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, sell-side analysts anticipate that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Friday. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of COMPASS Pathways in a research note on Friday, August 1st. HC Wainwright reduced their target price on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, August 4th. Finally, BTIG Research raised their target price on shares of COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $16.00.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.